EGFR and prostate carcinoma: Antibody-mediated inhibition of IGF-1R can result in significant inhibition of tumor growth in both androgen independent and dependent xenograft models [50,51] and IGF-1R/EGFR crosstalk has been associated with resistance to gefitinib in the well-characterized DU145 prostate cancer cell line.